Phase 1/2, Open-Label, Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ701 in Adults with ENPP1 Deficiency

被引：0
|
作者：
Sabbagh, Yves [1 ]
Wermers, Robert [2 ]
Fuhr, Rainard [3 ]
Schnabel, Dirk [4 ]
Arnason, Terra [5 ]
Besancon, Alix [6 ]
Cizman, Borut [1 ]
Wenkert, Deborah [7 ]
Gunter, Kurt [1 ]
机构：
[1] Inozyme Pharma, Boston, MA USA
[2] Mayo Clin, Rochester, MN USA
[3] Parexel Int GmbH, Early Phase Clin Unit, Berlin, Germany
[4] Charite, Ctr Chron Sick Children, Pediat Endocrinol, Berlin, Germany
[5] Univ Saskatchewan, Div Endocrinol, Saskatoon, SK, Canada
[6] Hop Univ Necker Enfants Malades, Endocrinodiabetol Pediat, Paris, France
[7] Wenkert & Young LLC, Thousand Oaks, CA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SUN-504
引用
收藏
页码：376 / 377
页数：2
相关论文
共 50 条
  • [31] Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
    Cohen, Fredric
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (01): : 87 - 94
  • [32] A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis
    Newsome, Scott
    Shoemaker, Thomas
    Tian, Fan
    Fitzgerald, Kate
    Bhargava, Pavan
    Snoops, Sarah
    Cooper, David
    Mammen, Jennifer
    Mowry, Ellen
    Calabresi, Peter
    NEUROLOGY, 2019, 92 (15)
  • [33] A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis
    Newsome, S. D.
    Tian, F.
    Fitzgerald, K. C.
    Bhargava, P.
    Shoemaker, T.
    Snoops, S.
    Cooper, D.
    Mammen, J.
    Mowry, E. M.
    Calabresi, P. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 18 - 18
  • [34] Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
    Duanduan Cong
    Jie Song
    Yue Liu
    Yan Tan
    Wei Xue
    Xiaohui Liu
    Wenyuan Qi
    Jun Lu
    Xiaojuan Yuan
    Yongchun Zhou
    Ai-Min Hui
    Kexin Li
    Neurology and Therapy, 2022, 11 : 283 - 301
  • [35] Phase 1, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib in adult subjects
    Gao, Ling
    Yamamiya, Ikuo
    Pinti, Mark
    Rondon, Juan Carlos
    Gareth, Thomas Marbury
    Tomlinson, Gareth
    Makris, Lukas
    Hangai, Nanae
    Wacheck, Volker
    CANCER RESEARCH, 2023, 83 (08)
  • [36] Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
    Cong, Duanduan
    Song, Jie
    Liu, Yue
    Tan, Yan
    Xue, Wei
    Liu, Xiaohui
    Qi, Wenyuan
    Lu, Jun
    Yuan, Xiaojuan
    Zhou, Yongchun
    Hui, Ai-Min
    Li, Kexin
    NEUROLOGY AND THERAPY, 2022, 11 (01) : 283 - 301
  • [37] A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF A SINGLE DOSE OF DAZODALIBEP IN HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS
    Der, K.
    Wang, Z.
    Bosoro, L.
    Hewitt, L.
    Wilson, T.
    Huang, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S79 - S79
  • [38] An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
    Simon, Marc A.
    Hanrott, Kate
    Budd, David C.
    Torres, Fernando
    Gruenig, Ekkehard
    Escribano-Subias, Pilar
    Meseguer, Manuel L.
    Halank, Michael
    Opitz, Christian
    Hall, David A.
    Hewens, Deborah
    Powley, William M.
    Siederer, Sarah
    Bayliffe, Andrew
    Lazaar, Aili L.
    Cahn, Anthony
    Rosenkranz, Stephan
    PULMONARY CIRCULATION, 2022, 12 (01)
  • [39] A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Skikne, Barry
    Cogle, Christopher R.
    Ning, Yuhong
    MacBeth, Kyle J.
    Laille, Eric
    Ward, M. Renee
    BLOOD, 2009, 114 (22) : 53 - 53
  • [40] A Phase 1, Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)
    Genge, Angela
    Berube-Desrosiers, Maxime
    Zinman, Lorne
    Shoesmith, Christen
    Salzman, Michael
    Schott, Robert
    Clermont, Paule
    Bingham, Justus
    Bowden, Emma
    NEUROLOGY, 2021, 96 (15)
12345